Precision and Agrivida enter into trait development collaboration based on precise gene modifications

Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease EditorTM (DNE) Technology. The collaboration recently delivered the first modified genes that are the subject of Agrivida commercialization efforts in the area of animal nutrition.

Agrivida is very pleased with the functional performance of Precision's DNE technology. "The efficiency, ease-of-use, and the demonstrated utility of the technology confirm the important role that precise genome engineering will have in the future of agricultural biotechnology", says Mike Lanahan, Agrivida VP of Business Development, Animal Nutrition. "Agrivida anticipates ongoing trait development using the technology in the collaboration with Precision."

"Precision is excited by Agrivida's results and we are thrilled to be working with an innovator in animal nutrition such as Agrivida," says Matthew Kane, Precision CEO. "We are optimistic that the combination Agrivida's unique understanding of plant metabolism and Precision's DNE gene editing technology can be utilized to develop a strong pipeline of greatly needed agricultural product candidates."

Dan Meagher, Agrivida CEO, says, "The opportunity for improving the nutritional characteristics of crops for the dairy and beef market segments is significant. Our results indicate that Precision technology has delivered a compositional modification that will benefit the industry by increasing the productivity of ruminant animals that consume plants expressing our trait."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths